kainos loboratories,inc Logo

kainos loboratories,inc

Develops, manufactures, and sells innovative clinical diagnostic reagents for the healthcare industry.

4556 | T

Overview

Corporate Details

ISIN(s):
JP3205650009
LEI:
Country:
Japan
Address:
文京区本郷二丁目38番18号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kainos Laboratories, Inc., founded in May 1975, is a company engaged in the research, development, manufacturing, and sale of clinical diagnostic products. It specializes in innovative clinical testing reagents, including biochemical and immunochemistry diagnostics, and also handles pharmaceuticals. The company's operations encompass the entire product lifecycle, from R&D to marketing, distribution, and import/export activities. Kainos Laboratories positions itself as a pioneer in its field, focused on creating innovative medical diagnostic tools for the healthcare industry.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 02:17
Registration Form
確認書
Japanese 8.1 KB
2025-11-06 02:16
Interim Report
半期報告書-第51期(2025/04/01-2026/03/31)
Japanese 157.7 KB
2025-06-20 03:02
Governance Information
内部統制報告書-第50期(2024/04/01-2025/03/31)
Japanese 21.9 KB
2025-06-20 03:00
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 02:59
Annual Report
有価証券報告書-第50期(2024/04/01-2025/03/31)
Japanese 710.6 KB
2025-06-20 02:56
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2024-11-06 01:39
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-11-06 01:38
Interim Report
半期報告書-第50期(2024/04/01-2025/03/31)
Japanese 160.1 KB
2024-06-21 03:08
Post-Annual General Meeting Information
臨時報告書
Japanese 22.5 KB
2024-06-21 03:06
Governance Information
内部統制報告書-第49期(2023/04/01-2024/03/31)
Japanese 21.1 KB
2024-06-21 03:04
Registration Form
確認書
Japanese 8.1 KB
2024-06-21 03:02
Annual Report
有価証券報告書-第49期(2023/04/01-2024/03/31)
Japanese 704.8 KB
2024-02-02 01:39
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-02-02 01:38
Quarterly Report
四半期報告書-第49期第3四半期(2023/10/01-2023/12/31)
Japanese 135.5 KB
2023-11-02 02:27
Report Publication Announcement
確認書
Japanese 8.0 KB

Automate Your Workflow. Get a real-time feed of all kainos loboratories,inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for kainos loboratories,inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for kainos loboratories,inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB

Talk to a Data Expert

Have a question? We'll get back to you promptly.